CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11 enrolled
Drug / intervention
Cancer Immunotherapy +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02431572
NCT02431572N/ACompleted
CompareCT.gov

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Massachusetts General Hospital·interventional·Posted May 1, 2015·Updated Apr 28, 2020

In Brief

A clinical study evaluating PBR PET, Cancer Immunotherapy, and 1 other intervention for Intracranial Tumors and 2 related conditions. Completed, enrolled 11 participants across 2 sites.

Detailed Summary

This research study is studying the changes in primary and metastatic brain tumor inflammation using positron emission tomography (PET) imaging using a radioactive substance called \[11C\] PBR28a, which is also known as peripheral benzodiazepine receptors (PBR), or PBR-PET.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracranial Tumors, Glioblastoma, Melanoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 1, 2015
Enrollment StartMay 1, 2015
Primary CompletionFeb 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.2 years ago

Interventions

PBR PETother

Cancer Immunotherapybiological

Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.

Radiation and chemotherapyradiation

Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.